About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 549 record(s)
Req # A-2021-000912
Adverse Drug Reactions (ADRs) for Emend. Report numbers: E2B_01892612, E2B_02240071, E2B_02276242. ADRs for Gardasil 9. Report numbers: 000722186, E2B_02316724, E2B_02415017, 000713885, 000714715, 000716382, 000717497, E2B_02217606, E2B_02284818.Organization: Health Canada
September 2023
Req # A-2021-002104
Adverse Drug Reactions (ADRs) for PETHIDINE HYDROCHLORIDE, FLUDARABINE PHOSPHATE, ZOPICLONE. Report numbers: E2B_04931776, E2B_04810161, E2B_04661733, E2B_02464087, E2B_04674007, E2B_04819558, E2B_04821402, E2B_04825593, E2B_04819559, E2B_04819779,…Organization: Health Canada
September 2023
Req # A-2022-000480
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-105261-759.Organization: Health Canada
September 2023
Req # A-2022-000600
Adverse Drug Reactions (ADRs). Report numbers: E2B_05218423, E2B_05234166, E2B_05293043, E2B_05302793, E2B_05168052, E2B_04998941, E2B_05206136, E2B_05118213, E2B_05239163, E2B_05249285.Organization: Health Canada
September 2023
Req # A-2022-001066
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-107475-990Organization: Health Canada
September 2023
Req # A-2022-001219
Adverse Drug Reaction (ADR). Report number: E2B_05625713.Organization: Health Canada
September 2023
Req # A-2022-001240
Adverse Drug Reaction (ADR). Report number: E2B_05020433.Organization: Health Canada
September 2023
Req # A-2022-001277
Adverse Drug Reactions (ADRs) for MORPHINE. Report numbers: E2B_05814334, E2B_05840954, E2B_05793140. ADR for NALTREXONE. Report number: 001012975. ADRs for HYDROMORPHONE. Report numbers: 001013828, E2B_05851510.Organization: Health Canada
September 2023
Req # A-2022-001448
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-075391-48.Organization: Health Canada
September 2023
Req # A-2022-001454
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-112856-848.Organization: Health Canada
September 2023